Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

ClinicalTrials.gov ID: NCT02906020

Public ClinicalTrials.gov record NCT02906020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant

Study identification

NCT ID
NCT02906020
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Genzyme, a Sanofi Company
Industry
Enrollment
273 participants

Conditions and interventions

Interventions

  • venglustat GZ/SAR402671 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 14, 2016
Primary completion
Dec 17, 2020
Completion
May 26, 2021
Last update posted
May 23, 2022

2016 – 2021

United States locations

U.S. sites
19
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Investigational Site Number :8400017 Scottsdale Arizona 85258
Investigational Site Number :8400011 Scottsdale Arizona 85259
Investigational Site Number :8400004 La Jolla California 92093
Investigational Site Number :8400019 Palo Alto California 94304
Investigational Site Number :8400013 Sunnyvale California 94085
Investigational Site Number :8400015 New Haven Connecticut 06510
Investigational Site Number :8400008 Boca Raton Florida 33486
Investigational Site Number :8400016 Chicago Illinois 60611
Investigational Site Number :8400005 Chicago Illinois 60612-3854
Investigational Site Number :8400014 Boston Massachusetts 02114
Investigational Site Number :8400018 New York New York 10003
Investigational Site Number :8400010 New York New York 10016
Investigational Site Number :8400001 New York New York 10032
Investigational Site Number :8400021 Portland Oregon 97210
Investigational Site Number :8400020 Portland Oregon 97225
Investigational Site Number :8400009 Portland Oregon 97239
Investigational Site Number :8400002 Philadelphia Pennsylvania 19107
Investigational Site Number :8400006 Fairfax Virginia 22030
Investigational Site Number :8400012 Kirkland Washington 98034

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 33 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02906020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 23, 2022 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02906020 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →